Cargando…

In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition

Drug development for the central nervous system (CNS) is a complex endeavour with low success rates, as the structural complexity of the brain and specifically the blood-brain barrier (BBB) poses tremendous challenges. Several in vitro brain systems have been evaluated, but the ultimate use of these...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murata, Yukiko, Neuhoff, Sibylle, Rostami-Hodjegan, Amin, Takita, Hiroyuki, Al-Majdoub, Zubida M., Ogungbenro, Kayode
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817058/ https://www.ncbi.nlm.nih.gov/pubmed/35028763 http://dx.doi.org/10.1208/s12248-021-00675-w

Ejemplares similares

Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling
por: Doki, Kosuke, et al.
Publicado: (2019)

Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters
por: Ahmad, Amais, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats
por: Scotcher, Daniel, et al.
Publicado: (2021)

A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine
por: Jamei, M., et al.
Publicado: (2013)

A “middle‐out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models
por: Yau, Estelle, et al.
Publicado: (2023)

Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment
por: El-Khateeb, Eman, et al.
Publicado: (2021)

Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to Human
por: Chen, Yang, et al.
Publicado: (2016)

Quantitative Proteomics of Hepatic Drug‐Metabolizing Enzymes and Transporters in Patients With Colorectal Cancer Metastasis
por: Vasilogianni, Areti‐Maria, et al.
Publicado: (2022)

Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects
por: Vasilogianni, Areti‐Maria, et al.
Publicado: (2021)

Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
por: Vasilogianni, Areti-Maria, et al.
Publicado: (2023)

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations
por: Scotcher, Daniel, et al.
Publicado: (2017)

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin
por: Rose, R H, et al.
Publicado: (2014)

Mass spectrometry‐based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin
por: Al‐Majdoub, Zubida M., et al.
Publicado: (2020)

Does “Birth” as an Event Impact Maturation Trajectory of Renal Clearance via Glomerular Filtration? Reexamining Data in Preterm and Full‐Term Neonates by Avoiding the Creatinine Bias
por: Salem, Farzaneh, et al.
Publicado: (2020)

Research tools for extrapolating the disposition and pharmacokinetics of nanomaterials from preclinical animals to humans
por: Valic, Michael S., et al.
Publicado: (2019)

Analysis of Time-Dependent Pharmacokinetics Using In Vitro–In Vivo Extrapolation and Physiologically Based Pharmacokinetic Modeling
por: Kim, Min-Chang, et al.
Publicado: (2022)

Investigation of simplified physiologically‐based pharmacokinetic models in rat and human
por: Yau, Estelle, et al.
Publicado: (2023)

Quantification of Proteins Involved in Intestinal Epithelial Handling of Xenobiotics
por: Al‐Majdoub, Zubida M., et al.
Publicado: (2020)

Interspecies extrapolation by physiologically based pharmacokinetic modeling
por: Ghallab, Ahmed
Publicado: (2015)

Microsomal and Cytosolic Scaling Factors in Dog and Human Kidney Cortex and Application for In Vitro-In Vivo Extrapolation of Renal Metabolic Clearance
por: Scotcher, Daniel, et al.
Publicado: (2017)

Population pharmacokinetics of everolimus in adult liver transplant patients: Comparison to tacrolimus disposition and extrapolation to pediatrics
por: Itohara, Kotaro, et al.
Publicado: (2022)

A Novel Physiologically Based Model of Creatinine Renal Disposition to Integrate Current Knowledge of Systems Parameters and Clinical Observations
por: Scotcher, Daniel, et al.
Publicado: (2020)

Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling
por: Bego, Margareta, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making
por: Rowland, M, et al.
Publicado: (2015)

Application of the Nested Enzyme‐Within‐Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic Effects
por: Takita, Hiroyuki, et al.
Publicado: (2020)

Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P‐Glycoprotein Activities
por: Achour, Brahim, et al.
Publicado: (2022)

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model
por: Chetty, Manoranjenni, et al.
Publicado: (2015)

Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models
por: Liu, Dan, et al.
Publicado: (2020)

Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation
por: Yoon, Miyoung, et al.
Publicado: (2016)

Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition
por: Yamazaki, Shinji, et al.
Publicado: (2021)

Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters
por: Achour, Brahim, et al.
Publicado: (2020)

Highlight report: Interspecies extrapolation by physiologically based pharmacokinetic modeling
por: Widera, Agata
Publicado: (2015)

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates
por: Tan, Ming‐Liang, et al.
Publicado: (2018)

Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine
por: Couto, Narciso, et al.
Publicado: (2020)

Corrigendum to: Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition
por: Yamazaki, Shinji, et al.
Publicado: (2022)

Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine‐Drug Interactions
por: Scotcher, Daniel, et al.
Publicado: (2020)

Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site
por: Musther, Helen, et al.
Publicado: (2015)

Application of an Accessible Interface for Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation
por: Hines, David E., et al.
Publicado: (2022)

Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically‐Based Pharmacokinetic Modeling and Dose Adjustment
por: Tan, Shawn Pei Feng, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
por: Chetty, Manoranjenni, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l3g0sinifgb07np2p4l0kq59ra